Pharming Group (NASDAQ:PHAR) Raised to “Hold (C-)” at Weiss Ratings

Pharming Group (NASDAQ:PHAR) was upgraded by stock analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating in a research report issued on Saturday,Weiss Ratings reports.

Separately, Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Pharming Group Stock Performance

Pharming Group stock opened at $13.60 on Friday. Pharming Group has a fifty-two week low of $7.31 and a fifty-two week high of $17.08. The stock’s 50 day simple moving average is $14.27 and its two-hundred day simple moving average is $11.62. The stock has a market cap of $931.74 million, a price-to-earnings ratio of -104.62 and a beta of 0.04. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,147 shares of the company’s stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.